Cipla Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is CELECOXIB USP, with a corresponding US DMF Number 16671.
Remarkably, this DMF maintains an Active status since its submission on June 30, 2003, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of September 28, 2013, and payment made on September 20, 2013, indicating their dedication to facilitating drug approvals, Categorized as Type II